stockrow
Friday 6 November 2026
Export IRWD’s income statement to Excel — free account
Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024.
- Revenue
- +9.00%
- EPS
- +45.2%
- Free cash flow
- +41.7%
- Total debt
- −44.4%
Quarter to September 2026, against a year earlier
4.36
0.33
+8.19%
Follow IRWD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(8.53%) | (37.07%) | (55.26%) | (82.81%) | |
Piotroski F-Score |
5 | 6 | 6 | 7 | |
| 6.42% | 26.83% | 41.35% | 43.58% | ||
ROIC |
57.33% | 84.97% | 101.61% | 111.28% | |
Return on Tangible Assets |
67.91% | 103.05% | 76.73% | 77.16% | |
Average Days of Receivables |
57.61 | 106.86 | 105.69 | 121.02 | |
Free Cash Flow per Share |
0.78 | 0.69 | 1.13 | 1.25 | |
Free Cash Flow |
127.01 | 112.21 | 185.56 | 205.37 | |
Capital Expenditures |
(0.03) | — | — | — | |
| Other line items | |||||
Cash ROIC |
23.59% | 19.08% | 61.38% | 65.37% | |
Accounts Receivable Turnover |
4.60 | 4.97 | 3.91 | 3.16 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.66) | (0.40) | (0.37) | (0.34) | |
Research and Development Expense of Revenue |
32.12% | 24.80% | 22.78% | 23.63% | |
Selling, General and Administrative Expense of Revenue |
27.78% | 19.37% | 16.58% | 13.54% | |
Share Based Compensation of Revenue |
5.82% | 4.32% | 3.68% | 3.75% | |
Interest Coverage |
3.01 | 5.92 | 7.17 | 8.28 | |
Operating CF/Net income |
5.29 | 1.10 | 1.43 | 1.37 | |
Depreciation/Fixed assets |
0.55 | 0.58 | 0.63 | 0.68 | |
Capex/Depreciation |
(0.02) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.83 | 2.21 | 2.37 | 2.43 | |
Operating CF per Share |
0.79 | 0.69 | 1.13 | 1.25 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026